Microbiotix signs licensing deal with Merck to develop antiviral candidates
Microbiotix gains worldwide rights to develop, manufacture and commercialize MBX-700 and MBX-701 that are designed to target NS5B polymerase enzyme and thereby restrain viral replication. Microbiotix president and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.